Phase i I, randomized trial comparing bevacizumab plus fluorouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 60-65

  Kabbinavar, Fairooz ^a   Hurwitz, Herbert I ^b   Fehrenbacher, Louis ^b   Meropol, Neal J ^b   Novotny, William F ^b   Lieberman, Grazyna ^b   Griffing, Susan ^b   Bergsland, Emily ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MORTALITY; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 0037208589     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.066     Document Type: Article

References (31)

1. Folkman J: Antiangiogenic therapy, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 3075-3085
2. Frank RE, Saclarides TJ, Leurgans S, et al: Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222:695-699, 1995
3. Takebayashi Y, Akiyama S, Yamada K, et al: Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 78: 226-231, 1996
4. Tanigawa N, Amaya H, Matsumura M, et al: Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 57:1043-1046, 1997
5. Tomisaki S, Ohno S, Ichiyoshi Y, et al: Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 77:1722-1728, 1996
6. Choi HJ, Hyun MS, Jung GJ, et al: Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 55:575-581, 1998
7. Fox SH, Whalen GF, Sanders MM, et al: Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 69:230-234, 1998
8. Abdalla SA, Behzad F, Bsharah S, et al: Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 6:839-842, 1999
9. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
10. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
11. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997
12. Takahashi Y, Kitadai Y, Bucana CD, et al: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964-3968, 1995
13. Takahashi Y, Tucker SL, Kitadai Y, et al: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132:541-546, 1997
14. Warren RS, Yuan H, Matli MR, et al: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797, 1995
15. Radinsky R, Ellis LM: Molecular determinants in the biology of liver metastasis. Surg Oncol Clin N Am 5:215-229, 1996
16. Tokunaga T, Oshika Y, Abe Y, et al: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77:998-1002, 1998
17. Borgström P, Gold DP, Hillan KJ, et al: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203-4214, 1999
18. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
19. Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 19:851-856, 2001
20. Petrelli N, Douglass HO, Herrera L, et al: Modulation of fluorouracil with leucovorin metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7:1419-1426, 1989
21. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
22. Chapuis PH, Dent OF, Fisher R, et al: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 72:698-702, 1985
23. Koch M, McPherson TA, Egedahl RD: Effect of sex and reproductive history on the survival of patients with colorectal cancer. J Chron Dis 35:69-72, 1982
24. Godwin JD II, Brown CC: Some prognostic factors in survival of patients with cancer of the colon and rectum. J Chron Dis 28:441-454, 1975
25. Evans WK, Nixon DW, Ellenberg SS, et al: A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 5:113-124, 1987
26. Lee C-G, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
27. Gerber H-P, Kowalski J, Sherman D, et al: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253-6258, 2000
28. DeVore R, Fehrenbacher L, Herbst RS, et al: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19:485a, 2000 (abstr 1896)
29. Levine MN: Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 78:133-136, 1997
30. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
31. Doulliard JY, Cunnigham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000